Efficacy and safety of risedronate 150-mg once a month in the treatment of postmenopausal osteoporosis: 2-year data

SUMMARY: This study showed that risedronate 150-mg once a month provides similar efficacy and safety at 2 years compared with risedronate 5-mg daily for the treatment of postmenopausal osteoporosis. This adds to the range of risedronate dosing options and provides an alternative for patients who pre...

Descripción completa

Detalles Bibliográficos
Autores principales: McClung, M. R., Zanchetta, J. R., Racewicz, A., Roux, C., Benhamou, C.-L., Man, Z., Eusebio, R. A., Beary, J. F., Burgio, D. E., Matzkin, E., Boonen, S., Delmas, P.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer-Verlag 2012
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3536944/
https://www.ncbi.nlm.nih.gov/pubmed/22752050
http://dx.doi.org/10.1007/s00198-012-2056-0

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3536944/
https://www.ncbi.nlm.nih.gov/pubmed/22752050
http://dx.doi.org/10.1007/s00198-012-2056-0

Ejemplares similares